The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis;Rola metaloproteinaz w modyfikacji macierzy zewna̧trzkomó rkowej w nowotworowym wzroście inwazyjnym, w przerzutowaniu i w angiogenezie

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 609-628

  Fink, Krzysztof ^a   Boratyński, Janusz ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Angiogenesis; Matrix metalloproteinases; MMP; Tumor

Indexed keywords

EID: 84867947572     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1009705     Document Type: Review

References (246)

1. Aimes R. T., Quigley J. P.: Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4-length fragments. J. Biol. Chem., 1995;270:5872-5876
2. Allan J. A., Docherty A. J., Barker P. J., Huskisson N. S., Reynolds J. J., Murphy G.: Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem. J., 1995;309:299-306
3. Allington T. M., Galliher-Beckley A. J., Schiemann W. P.: Activated Abl kinase inhibits oncogenic transforming growth factor-β signaling and tumorigenesis in mammary tumors. FASEB J., 2009;23:4231-4243
4. Altomare D. A., Testa J. R.: Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005;24:7455-7464
5. Angel P., Karin M.: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochem. Biophys. Acta, 1991;1072:129-157
6. Apte S. S., Mattei M. G., Olsen B. R.: Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics, 1994;19:86-90
7. Ardi V. C., Van den Steen P. E., Opdenakker G., Schweighofer B., Deryugina E. I., Quigley J. P.: Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J. Biol. Chem., 2009;284:25854-25866
8. Artym V. V., Zhang Y., Seillier-Moiseiwitsch F., Yamada K. M., Mueller S. C.: Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res., 2006;66:3034-3043
9. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J. M.: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J., 1999;18:3964-3972
10. Ayala I., Baldassarre M., Giacchetti G., Caldieri G., Tete S., Luini A., Buccione R.: Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J. Cell Sci., 2008;121:369-378
11. Baciu P. C., Suleiman E. A., Deryugina E. I., Strongin A. Y.: Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-αv integrin regulates cross-talk between αvβ3 and α2β1 integrins in breast carcinoma cells. Exp. Cell Res., 2003;291:167-175
12. Baker S. E., Hopkinson S. B., Fitchum M., Andreason G. L., Frasier F., Plopper G., Quaranta V., Jones J. C.: Laminin-5 and hemidesmosomes: role of the α3 chain subunit in hemidesmosome stability and assembly. J. Cell Sci., 1996;109:2509-2520
13. Baluk P., Hashizume H., McDonald D. M.: Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev., 2005;15:102-111
14. Basbaum C. B., Werb Z.: Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr. Opin. Cell Biol., 1996;8:731-738
15. Basile J. R., Holmbeck K., Bugge T. H., Gutkind J. S.: MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J. Biol. Chem., 2007;282:6899-6905
16. Basson C. T., Knowles W. J., Bell L., Albelda S. M., Castronovo V., Liotta L. A., Madri J. A.: Spatiotemporal segregation of endothelial cell integrin and nonintegrin extracellular matrix-binding proteins during adhesion events. J. Cell Biol., 1990;110:789-801
17. Bavik C., Coleman I., Dean J. P., Knudsen B., Plymate S., Nelson P. S.: The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res., 2006;66:794-802
18. Behrens J., von Kries J. P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W.: Functional interaction of β-catenin with the transcription factor LEF-1. Nature, 1996;382:638-642
19. Bergers G., Benjamin L. E.: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003;3:401-410
20. Bigg H. F., Shi Y. E., Liu Y. E., Steffensen B., Overall C. M.: Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. J. Biol. Chem., 1997;272:15496-15500
21. Blaine S. A., Ray K. C., Branch K. M., Robinson P. S., Whitehead R. H., Means A. L.: Epidermal growth factor receptor regulates pancreatic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2009;297:434-441
22. Blavier L., Lazaryev A., Shi X., De Clerck Y., Dorey F. J., Shackleford G. M.: Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol. Ther., 2010;10:198-208
23. Boone T. C., Johnson M. J., De Clerck Y. A., Langley K. E.: cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. Proc. Natl. Acad. Sci. USA, 1990;87:2800-2804
24. Bourboulia D., Stetler-Stevenson W. G.: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin. Canacer Biol., 2010;20:161-168
25. Bowden E. T., Barth M., Thomas D., Glazer R. I., Mueller S. C.: An invasion-related complex of cortactin, paxillin and PKCμ associates with invadopodia at sites of extracellular matrix degradation. Oncogene, 1999;18:4440-4449
26. Brassart B., Randoux A., Hornebeck W., Emonard H.: Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosaroma cell line. Clin. Exp. Metastasis, 1998;16:489-500
27. Brooks P. C., Strömblad S., Sanders L. C., von Schalscha T. L., Aimes R. T., Stetler-Stevenson W. G., Quigley J. P., Cheresh D. A.: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell, 1996;85:683-693
28. Calvete J. J., Fox J. W., Agelan A., Niewiarowski S., Marcinkiewicz C.: The presence of the WGD motif in CC8 heterodimeric disintegrin increases its inhibitory effect on αIIbβ3, αvβ3, and α5β1 integrins. Biochemistry, 2002;41:2014-2021
29. Carmeliet P., Jain R. K.: Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011;473:298-307
30. Cat B., Stuhlmann D., Steinbrenner H., Alili L., Holtkötter O., Sies H., Brenneisen P.: Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. J. Cell Sci., 2006;119:2727-2738
31. Cavaillon J. M.: Cytokines and macrophages. Biomed. Pharmacother., 1994;48:445-453
32. Cavallaro U., Christofori G.: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer, 2004;4:118-132
33. Chakraborti S., Mandal M., Das S., Mandal A., Charkraborti T.: Regulation of matrix metalloproteinases: an overview. Mol. Cell Biochem., 2003;253:269-285
34. Chen R. H., Su Y. H., Chuang R. L., Chang T. Y.: Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene, 1998;17:1959-1968
35. Chiang A. C., Massague J.: Molecular basis of metastasis. N. Engl. J. Med., 2008;359:2814-2823
36. Clark I. M., Swingler T. E., Sampieri C. L., Edwards D. R.: The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol., 2008;40:1362-1378
37. Coffelt S. B., Hughes R., Lewis C. E.: Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta, 2009;1796:11-18
38. Conery A. R., Cao Y., Thompson E. A., Townsend C. M. Jr., Ko T. C., Luo K.: Akt interacts directly with Smad3 to regulate the sensitivity to TGF-βeta induced apoptosis. Nat. Cell Biol., 2004;6:366-372
39. Conway E. M., Collen D., Carmeliet P.: Molecular mechanisms of blood vessel growth. Cardiovasc. Res., 2001;49:507-521
40. Crawford H. C., Fingleton B. M., Rudolph-Owen L. A., Goss K. J., Rubinfield B., Polakis P., Matrisian L. M.: The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene, 1999;18:2883-2891
41. Cretu A., Roth J. M., Caunt M., Akalu A., Policarpio D., Formenti S., Gagne P., Liebes L., Brooks P. C.: Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis. Clin. Cancer Res., 2007;13:3068-3078
42. Cuvier C., Jang A., Hill R. P.: Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L+B) secretion. Clin. Exp. Metastasis, 1997;15:19-25
43. Dean R. A., Butler G. S., Hamma-Kourbali H., Delbe J., Brigstock D. R., Courty J., Overall C. M.: Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol. Cell Biol., 2007;27:8454-8465
44. De Clerck D. A.: Interactions between tumour cells and stromal cells and proteolytic modifcation of the extracellular matrix by metalloproteinases in cancer. Eur. J. Cancer, 2000;36:1258-1268
45. Deryugina E. I., Quigley J. P.: Pleiotropic roles of matrix metalloproteinases in tumor angiogenesies: contrasting, overlapping and compensatory functions. Biochim. Biophysis. Acta, 2010;1803:103-120
46. Docherty A. J., Lyons A., Smith B. J., Wright E. M., Stephens P. E., Harris T. J., Murphy G., Reynolds J. J.: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature, 1985;318:66-69
47. Dong Z., Kumar R., Yang X., Fidler I. J.: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell, 1997;88:801-810
48. Douglas D. A., Shi Y. E., Sang Q. A.: Computational sequence analysis of the tissue inhibitor of metalloproteinase family. J. Protein Chem., 1997;276:8403-8408
49. Dumin J. A., Dickeson S. K., Striker T. P., Bhattacharyya-Pakrasi M., Roby J. D., Santoro S. A., Parks W. C.: Pro-collagenase 1 (matrix metalloproteinase-1) binds to the α2β1 integrin upon release from keratinocytes migrating on type I collagen. J. Biol. Chem., 2001;276:29368-29374
50. Dupont J., Pierre A., Froment P., Moreau C.: The insulin-like growth factor axis in cell cycle progression. Horm. Metab. Res., 2003;35:740-750
51. Egeblad M., Werb Z.: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002;2:161-174
52. Eguchi S., Dempsey P. J., Frank G. D., Motley E. D., Inagami T.: Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J. Biol. Chem., 2001;276:7957-7962
53. Eisenach P. A., Roghi C., Fogarasi M., Murphy G., English W. R.: MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J. Cell Sci., 2010;123:4182-4193
54. Elliott R. L., Blobe G. C.: Role of transforming growth factor β in human cancer. J. Clin. Oncol., 2005;23:2078-2093
55. Enenstein J., Kramer R. H.: Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J. Invest. Dermatol., 1994;103:381-386
56. Eswarakumar V. P., Lax I., Schlessinger J.: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev., 2005;16:139-149
57. Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M. A.: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl. Acad. Sci. USA, 2000;97:3884-3889
58. Fang K. C., Wolters P. J., Steinhoff M., Bidgol A., Blount J. L., Caughey G. H.: Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-β. J. Immunol., 1999;162:5528-5535
59. Ferrara N.: VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine Netw., 2009;20:158-163
60. Ferreras M., Felbor U., Lenhard T., Olsen B. R., Delaisse J.: Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett., 2000;486:247-251
61. Fischer C., Mazzone M., Jonckx B., Carmeliet P.: FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nature Rev. Cancer, 2008;8:942-956
62. Foda H. D., Zucker S.: Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov. Today, 2001;6:478-482
63. Folkman J.: Tumor angiogenesis. Adv. Cancer Res., 1974;19:331-358
64. Forsythe J. A., Jiang B., Iyer N. V., Agani F., Leung S. W., Koos R. D., Semenza G. L.: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol., 1996;16:4604-4613
65. Fowlkes J. L., Enghild J. J., Suzuki K., Nagase H.: Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem., 1994;269:25742-25746
66. Friedl P., Gilmour D.: Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol., 2009;10:445-457
67. Gaengel K., Genove G., Armulik A., Betsholtz C.: Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol., 2009;29:630-638
68. Gialeli C., Theocharis A. D., Karamanos N. K.: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J., 2011;278:16-27
69. Giampieri S., Pinner S., Sahai E.: Intravital imaging illuminates transforming growth factor b signaling switches during metastasis. Cancer Res., 2010;70:3435-3439
70. Giancotti F. G., Tarone G.: Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu. Rev. Cell Dev. Biol., 2003;19:173-206
71. Giannelli G., Fransvea E., Marinosci F., Bergamini C., Colucci S., Schiraldi O., Antonaci S.: Transforming growth factor-b1 triggers hepatocellular carcinoma invasiveness via a3b1 integrin. Am. J. Pathol., 2002;161:183-193
72. Gilles C., Polette M., Coraux C., Tournier J. M., Meneguzzi G., Munaut C., Volders L., Rousselle P., Birembaut P., Foidart J. M.: Contribution of MT1-MMP and a human laminin-5 g2 chain degradation to mammary epithelial cell migration. J. Cell Sci., 2001;114:2967-2976
73. Goerge T., Barg A., Schnaeker E. M., Poppelmann B., Shpacovitch V., Rattenholl A., Maaser C., Luger T. A., Steinhoff M., Schneider S. W.: Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res., 2006;66:7766-7774
74. Gohlke U., Gomis Ruth F. X., Crabbe T., Murphy G., Docherty A. J., Bode W.: The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett., 1996;378:126-130
75. Gonzalez E. M., Reed C. C., Bix G., Fu J., Zhang Y., Gopalakrishnan B., Greenspan D. S., Iozzo R. V.: BMP-1/tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J. Biol. Chem., 2005;280:7080-7087
76. Gorelik L., Flavell R. A.: Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med., 2001;7:1118-1122
77. Gould R. J., Polokoff M. A., Friedman P. A., Huang T. F., Holt J. C., Cook J. J., Niewiarowski S.: Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med., 1990;195:168-171
78. Grant D. S., Tashiro K., Segui-Real B., Yamada Y., Martin G. R., Kleinman H. K.: Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell, 1989;58:933-943
79. Greene J., Wang M., Liu Y. E., Raymond L. A., Rosen C., Shi Y. E.: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem., 1996;271:30375-30380
80. Groblewska M., Mroczko B., Szmitkowski M.: Rola wybranych metaloproteinaz i ich inhibitorów w rozwoju raka jelita grubego. Postȩpy Hig. Med. Dośw., 2010;64:22-30
81. Gruber B. L., Marchese M. J., Suzuki K., Schwartz L. B., Okada Y., Nagase H., Ramamurthy N. S.: Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J. Clin. Invest., 1999;84:1657-1662
82. Hamano Y., Kalluri R.: Tumstatin, the NC1 domain of α3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem. Biophys. Res. Commun., 2005;333:292-298
83. Hanahan D.: Signaling vascular morphogenesis and maintenance. Science, 1997;277:48-50
84. Hangai M., Kitaya N., Xu J., Chan C. K., Kim J. J., Werb Z., Ryan S. J., Brooks P. C.: Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol., 2002;161:1429-1437
85. Harrell P. C., McCawley L. J., Fingleton B., McIntyre J. O., Matrisian L. M.: Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. Exp. Cell Res., 2005;303:308-320
86. Hawinkels L. J., Kuiper P., Wiercinska E., Verspaget H. W., Liu Z., Pardali E., Sier C. F., ten Dijke P.: Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res., 2010;70:4141-4150
87. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N. R., Crystal R. G., Besmer P., Lyden D., Moore M. A., Werb Z., Rafii S.: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 2002;109:625-637
88. Hellberg C., Ostman A., Heldin C. H.: PDGF and vessel maturation. Recent results. Cancer Res., 2010;180:103-114
89. Heppner K. J., Matrisian L. M., Jensen R. A., Rodgers W. H.: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol., 1996;149:273-282
90. Hernandez-Barrantes S., Bernardo M., Toth M., Fridman R.: Regulation of membrane-type matrix metalloproteinases. Sem. Cancer Biol., 2002;12:131-138
91. Hirschi K. K., D'Amore P. A.: Pericytes in the microvasculature. Cardiovasc. Res., 1996;32:687-698
92. Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999;284:1994-1998
93. Holash J., Wiegand S. J., Yancopoulos G. D.: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene, 1999;18:5356-5362
94. Hornebeck W., Emonard H., Monboisse J. C., Bellon G.: Matrixdirected regulation of pericellular proteolysis and tumor progression. Semin. Cancer Biol., 2002;12:231-241
95. Hua H., Li M., Luo T., Yin Y.: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell, Mol. Life Sci., 2011;63:3853-3868
96. Huang S., Van Arsdall M., Tedjarati S., McCarty M., Wu W., Langley R., Fidler I. J.: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst., 2002;94:1134-1142
97. Imai K., Hiramatsu A., Fukushima D., Pierschbacher M. D. Okada Y.: Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochem. J., 1997;322:809-814
98. Ishiyama N., Lee S. H., Liu S., Li G. Y., Smith M. J., Reichardt L. F., Ikura M.: Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell, 2010;141:117-128
99. Jain R. K.: Molecular regulation of vessel maturation. Nature Med., 2003;9:685-693
100. Jakobsson L., Franco C. A., Bentley K., Collins R. T., Ponsioen B., Aspalter I. M., Rosewell I., Busse M., Thurston G., Medvinsky A., Schulte-Merker S., Gerhardt H.: Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nature Cell Biol., 2010;12:943-953
101. Janda E., Lehmann K., Killisch I., Jechlinger M., Herzig M., Downward J., Beug H., Grunert S.: Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol., 2002;156:299-313
102. Jiang A., Lehti K., Wang X., Weiss S. J., Keski-Oja J., Pei D.: Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc. Natl. Acad. Sci. USA, 2001;98:13693-13698
103. Jung S., Rutka J. T., Hinek A.: Tropoelastin and elastin degradation products promote proliferation of human astrocytoma cell lines. J. Neuropathol. Exp. Neurol., 1998;57:439-448
104. Kajita M., Itoh Y., Chiba T., Mori H., Okada A., Kinoh H., Seiki M.: Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol., 2001;153:893-904
105. Kaplan R. N., Rafii S., Lyden D.: Preparing the 'soil': the premetastatic niche. Cancer Res., 2006;66:11089-11093
106. Kataoka H., Uchino H., Iwamura T., Seiki M., Nabeshima K., Koono M.: Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of α1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am. J. Pathol., 1999;154:457-468
107. Kessenbrock K., Plaks V., Werb Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 2010;141:52-67
108. Kim E. S., Sohn Y. W., Moon A.: TGF-β-induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF) 2 in human breast epithelial cells. Cancer Lett., 2007;252:147-156
109. Kim I. Y., Yong H. Y., Kang K. W., Moon A.: Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett., 2009;275:227-233
110. Kim Y. M., Jang J. W., Lee O. H., Yeon J., Choi E. Y., Kim K. W., Lee S. T., Kwon Y. G.: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. Cancer Res., 2000;60:5410-5413
111. Klein S., Roghani M., Rifkin D. B.: Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. EXS, 1997;79:159-192
112. Kołaczkowska E.: Metaloproteinaza 9 (MMP-9) jako szczególny przedstawiciel metaloproteinaz macierzy zewna̧trzkomórkowej: rola w napływie i apoptozie neutrofili w trakcie reakcji zapalnej. Postȩpy Biol. Kom., 2010;2:471-499
113. Krzyżanowska-Goła̧b D., Lemańska-Perek A., Ka̧tnik-Prastowska I.: Fibronektyna jako aktywny składnik macierzy pozakomórkowej. Postȩpy Hig. Med. Dośw., 2007;61:655-663
114. Labrecque L., Nyalendo C., Langlois S., Durocher Y., Roghi C., Murphy G., Gingras D., Beliveau R.: Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J. Biol. Chem., 2004;279:52132-52140
115. La Flamme S. E., Auer K. L.: Integrin signaling. Semin. Cancer Biol., 1996;7:111-118
116. Lafleur M. A., Xu D., Hemler M. E.: Tetraspanin proteins regulate membrane type-1 matrix metalloproteinase-dependent pericellular proteolysis. Mol. Biol. Cell, 2009;20:2030-2040
117. Leco K. J., Waterhouse P., Sanchez O. H., Gowing K. L., Poole A. R., Wakeham A., Mak T. W., Khokha R.: Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J. Clin. Invest., 2001;108:817-829
118. Lee S., Jilani S. M., Nikolova G. V., Carpizo D., Iruela-Arispe M. L.: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol., 2005;169:681-691
119. Levi E., Fridman R., Miao H. Q., Ma Y. S., Yayon A., Vlodavsky I., Miao H. Q., Ma Y. S.: Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. USA, 1996;93:7069-7074
120. Lichtenberger B. M., Tan P., Niederleithner H., Ferrara N., Petzelbauer P., Sibila M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell, 2010;140:268-279
121. Lipka D., Boratyński J.: Metaloproteinazy MMP. Struktura i funkcja. Postȩpy Hig. Med. Dośw., 2008;62:328-336
122. Liu D., Hornsby P. J.: Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res., 2007;67:3117-3126
123. Lochter A., Galosy S., Muschler J., Freedman N., Werb Z., Bissell M.: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol., 1997;139:1861-1872
124. Lopez-Otin C., Overall C. M.: Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol., 2002;3:509-519
125. Lu D., Scully M., Kakkar V., Lu X.: ADAM-15 disintegrin-like domain structure and function. Toxins, 2010;2:2411-2427
126. Luo J. L., Maeda S., Hsu L. C., Yagita H., Karin M.: Inhibition of NF-κB in cancer cells converts infammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell, 2004;6:297-305
127. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N. R., Crystal R. G., Moore M. A., Hajjar K. A., Manova K., Benezra R., Rafii S.: Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med., 2001;7:1194-1201
128. Lynch C. C., Matrisian L. M.: Matrix metalloproteinases in tumor-host cell communication. Differentiation, 2002;70:561-573
129. Łukaszewicz M., Mroczko B., Szmitkowski M.: Rola metaloproteinaz i ich inhibitrów w raku trzustki. Postȩpy Hig. Med. Dośw., 2003;62:141-147
130. łukaszewicz-Zaja̧c M., Mroczko B., Szmitkowski M.: Znaczenie metaloproteinaz oraz ich inhibitorów w raku żoła̧dka. Postȩpy Hig. Med. Dośw., 2009;63:258-265
131. Maeshima Y., Colorado P. C., Kalluri R.: Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem., 2000;275:23745-23750
132. Magzoub M., Jin S., Verkman A. S.: Enhanced macromolecule diffusion deep in t umors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J., 2008;22:276-284
133. Maisonpierre P. C., Suri C., Jones P. F., Bartunkova S., Wiegand S., Radziejewski C., Compton D., McClain J., Aldrich T. H., Papadopoulos N., Daly T. J., Davis S., Sato T. N., Yancopoulos G. D.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 1997;277:55-60
134. Makrilia N., Kollias A., Manolopoulos L., Syrigos K.: Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest., 2009;27:1023-1037
135. Manes S., Mira E., Barbacid M. M., Cipres A., Fernandez-Resa P., Buesa J. M., Merida I., Aracil M., Marquez G., Martinez A. C.: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem., 1997;272:25706-25712
136. Manicone A. M., McGuire J. K.: Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol., 2008;19:34-41
137. Marchenko G. N., Ratnikov B. I., Rozanov D. V., Godzik A., Deryugina E. I., Strongin A. Y.: Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem. J., 2001;356:705-718
138. Marneros A. G., Olsen B. R.: The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol., 2001;20:337-345
139. Masson V., de la Ballina L. R., Munaut C., Wielockx B., Jost M., Maillard C., Blacher S., Bajou K., Itoh T., Itohara S., Werb Z., Libert C., Foidart J. M., Noël A.: Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J., 2005;18:234
140. May C. D., Sphyris N., Evans K. W., Werden S. J., Guo W., Mani S. A.: Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res., 2011;13:202
141. McLane M. A., Sanchez E. E., Wong A., Paquette-Straub C., Perez J. C.: Disintegrins. Curr. Drug Targets Cardiovasc. Haematol. Disord., 2004;4:327-355
142. McQuibban G. A., Gong J. H., Wong J. P., Wallace J. L., Clark-Lewis I., Overall C. M.: Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood, 2002;100:1160-1167
143. Miettinen P. J., Ebner R., Lopez A. R., Derynck R.: TGF-βeta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol., 1994;127:2021-2036
144. Mira E., Manes S., Lacalle R. A., Marquez G., Martinez A. C.: Insulinlike growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology, 1999;140:1657-1664
145. Mori K., Shibanuma M., Nose K.: Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res., 2004;64:7464-7472
146. Motrescu E. R., Rio M. C.: Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol. Chem., 2008;389:1037-1041
147. Murakami, M., Nguyen L. T., Zhang Z. W., Moodie K. L., Carmeliet P., Stan R. V., Simons M.: The FGF system has a key role in regulating vascular integrity. J. Clin. Invest., 2008;118:3355-3366
148. Murphy G., Knauper V.: Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol., 1997;15:511-518
149. Nagase H.: Activation mechanisms of matrix metalloproteinases. Biol. Chem. Hoppe Seyler, 1997;378:151-160
150. Nagy J. A., Dvorak A. M., Dvorak H. F.: VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol., 2007;2:251-275
151. Nawrocki-Raby B., Gilles C., Polette M., Bruyneel E., Laronze J. Y., Bonnet N., Foidart J. M., Mareel M., Birembaut P.: Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int. J. Cancer, 2003;105:790-795
152. Newby A. C.: Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol., 2008;28:2108-2114
153. Niewiarowski S., McLane M. A., Kloczewiak M., Stewart G. J.: Disintegrins and other naturally occuring antagonists of platelet fibrinogen receptors. Semin. Hematol., 1994;31:289-300
154. Nikai T., Taniguchi K., Komori Y., Masuda K., Fox J. W., Sugihara H.: Primary structure and functional characterization of bilitoxin-1, a novel dimeric P-II snake venom metalloproteinase from Agkistrodon bilineatus venom. Arch. Biochem. Biophys., 2000;378:6-15
155. Noel A., Jost M., Maquoi E.: Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol., 2008;19:52-60
156. Nyalendo C., Beaulieu E., Sartelet H., Michaud M., Fontaine N., Gingras D., Beliveau R.: Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis, 2008;29:1655-1664
157. Nyberg P., Heikkila P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U. H., Pihlajaniemi T., Salo T.: Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J. Biol. Chem., 2003;278:22404-22411
158. Olson M. W., Toth M., Gervasi D. C., Sado Y., Ninomiya Y., Fridman R.: High affinity binding of latent matrix metalloproteinase-9 to the a2 (IV) chain of collagen IV. J. Biol. Chem., 1998;273:10672-10681
159. Onimaru M., Yonemitsu Y., Suzuki H., Fujii T., Sueishi K.: An autocrine linkage between matrix metalloproteinase-14 and Tie-2 via ectodomain shedding modulates angiopoietin-1-dependent function in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2010;30:818-826
160. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994;79:315-328
161. Oshikawa K.; Terada S.: Ussuristatin 2, a novel KGD-bearing disintegrin from Agkistrodon ussuriensis venom. J. Biochem., 1999;125:31-35
162. Overall C. M., Lopez-Otin C.: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer, 2002;2:657-672
163. Papaspyridonos M., Lyden D.: The role of bone marrow-derived cells in tumor angiogenesis and metastatic progression. Methods Enzymol., 2008;444:255-269
164. Pei D., Weiss S. J.: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature, 1995;375:244-247
165. 2+ flux but not mitogenesis. Nature, 1992;358:678-681
166. Petitclerc E., Boutaud A., Prestayko A., Xu J., Sado Y., Ninomiya Y., Sarras M. P. Jr., Hudson B. G., Brooks P. C.: New functions for non-collagenous domains of human collagen IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem., 2000;275:8051-8061
167. Phng L. K., Gerhardt H.: Angiogenesis: a team effort coordinated by Notch. Dev. Cell, 2009;16:196-208
168. Pietenpol J. A., Stein R. W., Moran E., Yaciuk P., Schlegel R., Lyons R. M., Pittelkow M. R., Münger K., Howley P. M., Hoses H. L.: TGF-β 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 1990;61:777-785
169. Poincloux R., Lizarraga F., Chavrier P.: Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J. Cell Sci., 2009;122:3015-3024
170. Polette M., Nawrocki-Raby B., Gilles C., Clavel C., Birembaut P.: Tumour invasion and matrix metalloproteinases. Crit. Rev. Oncol. Hematol., 2003;49:179-186
171. Powell U. C., Fingleton B., Wilson C. L., Boothby M., Matrisian L. M.: The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol., 1999;9:1441-1447
172. Purhonen S., Palm J., Rossi D., Kaskenpaa N., Rajantie I., Yla-Herttuala S., Alitalo K., Weissman I. L., Salven P.: Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl. Acad. Sci. USA, 2008;105:6620-6625
173. Qi J. H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., Baker A., Anand-Apte B.: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med., 2003;9:407-415
174. Radisky D. C., Levy D. D., Littlepage L. E., Liu H., Nelson C. M., Fata J. E., Leake D., Godden E. L., Albertson D. G., Nieto M. A., Werb Z., Bissell M. J.: Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature, 2005;436:123-127
175. Radisky E. S., Radisky D. C.: Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia, 2010;15:201-212
176. Rathinam R., Alahari S. K.: Important role of integrins in the cancer biology. Cancer Metastasis Rev., 2010;29:223-237
177. Ratnikov B. I., Rozanov D. V., Postnova T. I., Baciu P. G., Zhang H., Di Scipio R. G., Chestukhina G. G., Smith J. W., Deryugina E. I., Strongin A. Y.: An alternative processing of integrin an subunit in tumor cells by membrane type-1 matrix metalloproteinase. J. Biol. Chem., 2002;277:7377-7385
178. Ribeiro A. S., Albergaria A., Sousa B., Correia A. L., Bracke M., Seruca R., Schmitt F. C., Paredes J.: Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene, 2010;29:392-402
179. Risau W.: Mechanisms of angiogenesis. Nature, 1997;386:671-674
180. Rolli M., Fransvea E., Pilch J., Saven A., Felding-Habermann B.: Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003;100:9482-9487
181. Rozanov V. D., Hahn-Dantona E., Strickland D. K., Strongin A. Y.: The low-density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J. Biol. Chem., 2004;279:4260-4268
182. Sabbota A. L., Kim H. R., Zhe X., Fridman R., Bonfil R. D., Cher M. L.: Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res., 2010;70:5558-5566
183. Samani A. A., Yakar S., Le Roith D., Brodt P.: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev., 2007;28:20-47
184. Sanderson R. D., Yang Y., Kelly T., MacLeod V., Dai Y., Theus A.: Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell. Biochem., 2005;96:897-905
185. Sato H., Takino T.: Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci., 2010;101:843-847
186. Schenk S., Quaranta V.: Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol., 2003;13:366-375
187. Sheu B. C., Hsu S. M., Ho H. N., Lien H. C., Huang S. C., Lin R. H.: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res., 2001;61:237-242
188. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M. G., Rimoldi M., Biswas S. K., Allavena P., Mantovani A.: Macrophage polarization in tumour progression. Sem. Cancer Biol., 2008;18:349-355
189. Siigur E., Aaspollu A., Tu A. T., Siigur J.: cDNA cloning and deduced amino acid sequence of fibrinolytic enzyme (lebetase) from Vipera lebetina snake venom. Biochem. Biophys. Res. Commun., 1996;224:229-236
190. Skóra J., Biegus J., Pupka A., Barć P., Sikora J., Szyber P.: Molekularne podstawy angiogenezy. Postȩpy Hig. Med. Dośw., 2006;60:410-415
191. Song S., Ewald A. J., Stallcup W., Werb Z., Bergers G.: PDGFRb+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biol., 2005;7:870-879
192. Sottrup-Jensen L., Birkedal-Hansen H.: Human fibroblast collagenase-α-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian α-macroglobulins. J. Biol. Chem., 1989;264:393-401
193. Sounni N., Paye A., Host L., Noël A.: MT-MMP as regulators of vessel stability associated with angiogenesis. Front. Pharmacol., 2011;2:111
194. Sounni N. E., Rozanov D. V., Remacle A. G., Golubkov V. S., Noel A., Strongin A. Y.: Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int. J. Cancer, 2010;126:1067-1078
195. Sternlicht M. D., Werb Z.: How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001;17:463-516
196. Stromblad S., Cheresh D. A.: Integrins, angiogenesis and vascular cell survival. Chem. Biol., 1996;3:881-885
197. Strongin A. Y., Collier I., Bannikov G., Marmer B. L., Grant G. A., Goldberg G. I.: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem., 1995;270:5331-5338
198. Stylli S. S., Kaye A. H., Lock P.: Invadopodia: at the cutting edge of tumour invasion. J. Clin. Neurosci., 2008;15:725-737
199. Suri C., Jones P. F., Patan S., Bartunkova S., Maisonpierre P. C., Davis S., Sato T. N., Yancopoulos G. D.: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 1996;87:1171-1180
200. Suzuki K., Lees M., Newlands G. F., Nagase H., Woolley D. E.: Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem. J., 1995;305:301-306
201. Suzuki M., Raab G., Moses M. A., Fernandez C. A., Klagsbrun M.: Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem., 1997;272:31730-31737
202. Takahashi M., Tsunoda T., Seiki M., Nakamura Y., Furukawa Y.: Identification of membrane-type matrix metalloproteinase-1 as a target of the β-catenin/Tcf4 complex in human colorectal cancers. Oncogene, 2002;21:5861-5867
203. Takino T., Tsuge H., Ozawa T., Sato H.: MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem. Biophys. Res. Commun., 2010;396:1042-1047
204. Tholozan F. M., Gribbon C., Li Z., Goldberg M. W., Prescott A. R., McKie N., Quinlan R. A.: FGF-2 release from the lens capsule by MMP-2 maintains lens epithelial cell viability. Mol. Biol. Cell, 2007;18:4222-4231
205. Thomas K. A.: Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem., 1996;271:603-606
206. Thrailkill K. M., Quarles L. D., Nagase H., Suzuki K., Serra D. M., Fowlkes J. L.: Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology, 1995;136:3527-3533
207. Totoń E., Rybczyńska M.: Charakterystyka białka FAK i jego rola w procesie nowotworzenia. Postȩpy Hig. Med. Dośw., 2007;61:303-309
208. Tsunezuka Y., Kinoh H., Takino T., Watanabe Y., Okada Y., Shinagawa A., Sato H., Seiki M.: Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res., 1996;56:5678-5683
209. Turner N., Grose R.: Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 2010;10:116-129
210. Tvorogov D., Anisimov A., Zheng W., Leppanen V. M., Tammela T., Laurinavicius S., Holnthoner W., Helotera H., Holopainen T., Jeltsch M., Kalkkinen N., Lankinen H., Ojala P. M., Alitalo K.: Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell, 2010;18:630-640
211. Uekita T., Itoh Y., Yana I., Ohno H., Seiki M.: Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J. Cell Biol., 2001;155:1345-1356
212. Ungefroren H., Sebens S., Seidl D., Lehnert H., Hass R.: Interaction of tumor cells with the microenvironment. Cell Commun. Signal., 2011;9:18
213. Uria J. A., Stahle-Backdahl M., Seiki M., Fueyo A., Lopez-Otin C.: Regulation of collagenase-3 in human breast carcinomas is mediated by stroma-epithelial cell interactions. Cancer Res., 1997;57:4882-4888
214. Van Lint P., Libert C.: Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev., 2006;17:217-223
215. Visse R., Nagase H.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003;92:827-839
216. von Bredow D. C., Nagle R. B., Bowden G. T., Cress A. E.: Cleavage of β4 integrin by matrilysin. Exp. Cell Res., 1997;236:341-345
217. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K. E., Geber A., Fligelman B., Leveresha M., Brennan C., Tabar V.: Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 2010;468:829-833
218. Wastermack J., Kahari V. M.: Regulatin of matrix metalloproteinase expression in tumor invasion. FASEB J., 1999;13:781-792
219. Weber C. E., Kuo P. C.: The tumor microenvironment. Surg. Oncol., 2012;21:172-177
220. Weiss S. J., Peppin G., Ortiz X., Ragsdale C., Test S. T.: Oxidative autoactivation of latent collagenase by human neutrophils. Science, 1985;227:747-749
221. Whitelock J. M., Murdoch A. D., Iozzo R. V., Underwood P. A.: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases. J. Biol. Chem., 1996;271:10079-10086
222. Wickstrom S. A., Alitalo K., Keski-Oja J.: Endostatin associates with integrin α5β1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res., 2002;62:5580-5589
223. Wideł M. S., Wideł M.: Mechanizmy przerzutowania i molekularne markery progresji nowotworów złośliwych. I. Rak jelita grubego. Postȩpy Hig. Med. Dośw., 2006;60:453-470
224. Will H., Hinzmann B.: cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur. J. Biochem., 1995;231:602-608
225. Willis B. C., du Bois R. M., Borok Z.: Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc., 2006;3:377-382
226. Witty J. P., Lempka T., Coffey R. J. Jr., Matrisian L. M.: Decreased tumor formation in 7, 12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res., 1995;55:1401-1406
227. Wolf K., Wu Y. I., Liu Y., Geiger J., Tam E., Overall C., Stack M. S., Friedl P.: Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol., 2007;9:893-904
228. Wu X., Gan B., Yoo Y., Guan J. L.: FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation. Dev. Cell, 2005;9:185-196
229. Wyckoff J. B., Wang Y., Lin E. Y., Li J. F., Goswami S., Stanley E. R., Segall J. E., Pollard J. W., Condeelis J.: Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res., 2007;67:2649-2656
230. Xian X., Hakansson J., Stahlberg A., Lindblom P., Betsholtz C., Gerhardt H., Semb H.: Pericytes limit tumor cell metastasis. J. Clin. Invest., 2006;116:642-651
231. Xu J., Rodriguez D., Petitclerc E., Kim J. J., Hangai M., Moon Y. S., Davis G. E., Brooks P. C.: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol., 2001;154:1069-1079
232. Yancopoulos G. D., Davis S., Gale N. W., Rudge J. S., Wiegand S. J., Holash J.: Vascular-specific growth factors and blood vessel formation. Nature, 2000;407:242-248
233. Yañez-Mó M., Barreiro O., Gonzalo P., Batista A., Meqias D., Genis L., Sachs N., Sala-Valdés M., Alonso M. A., Montoya M. C., Sonnenberg A., Arroyo A. G., Sánchez-Madrid F.: MT1-MMP collagenolytic activity is regulated through association with tetraspanin CD151 in primary endothelial cells. Blood, 2008;112:3217-3226
234. Yang Z., Strickland D. K., Bornstein P.: Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem., 2001;276:8403-8408
235. Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S. E., Henney A. M.: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem., 1996;271:13055-13060
236. Yeh W. L., Lu D. Y., Lee M. J., Fu W. M.: Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia, 2009;57:454-464
237. Yoon S. O., Park S. J., Yun C. H., Chung A. S.: Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol., 2003;36:128-137
238. Yu Q., Stamenkovic I.: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev., 2000;14:163-176
239. Zhang D., Bar-Eli M., Meloche S., Brodt P.: Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J. Biol. Chem., 2004;279:19683-19690
240. Zhao H., Bernardo M. M., Osenkowski P., Sohail A., Pei D., Nagase H., Kashiwagi M., Soloway P. D., De Clerck Y. A., Fridman R.: Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloroteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. J. Biol. Chem., 2004;279:8592-8601
241. Zhou Z., Apte S. S., Soininen R., Cao R., Baaklini G. Y., Rauser R. W., Wang J., Cao Y., Tryggvason K.: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. USA, 2000;97:4052-4057
242. Ziche M., Morbidielli L., Choudhuri R., Zhang H. T., Donnini S., Grnager H. J., Bicknell R.: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest., 1997;99:2625-2634
243. Zielonka T. M.: Angiogeneza - Czȩść I. Mechanizm powstawania nowych naczyń krwionośnych. Alergia Astma Immunologia, 2003;8:169-174
244. Zigrino P., Löffek S., Mauch C.: Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie, 2005;87:321-328
245. Zutter M. M., Santoro S. A., Staatz W. D., Tsung Y. L.: Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. USA, 1995;92:7411-7415
246. Żebrowska A., Wysoczyńska K., Waszczykowska E.: Adamalizyny - metaloproteinazy biora̧ce udział w patofizjologii chorób skóry. Alergia Astma Immunologia, 2005;10:187-193